Polymerase Chain Reaction (PCR) Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,850	135 Pages	Fortune Business Insights Pvt. Ltd.	October, 2024	FOB19224242

Best Price Guarantee
Price	from $4,850
Length	135 Pages
Publisher	Fortune Business Insights Pvt. Ltd.
Published Date	October, 2024
SKU	FOB19224242

Polymerase Chain Reaction (PCR) Market

Growth Factors of Polymerase Chain Reaction (PCR) Market

The polymerase chain reaction (PCR) market size was valued at USD 9.15 billion in 2023, and the market is now projected to rise from USD 9.91 billion in 2024 to USD 19.23 billion by 2032, exhibiting a CAGR of 8.6% during the forecast period of 2023-2032.

Due to the covid pandemic many companies shut down their prediction units and projects due to hindered travel acquisitions which ultimately created a decline in the polymerase chain reaction (PCR) market growth. Government has put restrictions on social gatherings, events and moving out from home which make the people homesick. Numerous companies are encountering hurdles due to covid pandemic as the outbreak situation has curtailed production and supply chain which has hindered the polymerase chain reaction (PCR) market switched to treating covid patients as priority over the other procedures which led the polymerase chain reaction (PCR) market growth.

PCR is a well-known innovative approach to work for the amplification of DNA for detection of various trace elements. PCR is an enzyme based rection in which enzyme plays a key role in the process. Developments in methods to quicken market expansion. A little section of DNA can be amplified in vitro using the polymerase chain reaction, an enzyme-driven technique. Even with this amplification capability, the technology can't advance to its full potential because to constraints in the accompanying hardware. The necessity to introduce new items has arisen from technological developments and the rising demand for cutting-edge gadgets. Over the projected period, the demand for personalized pharmaceuticals, improved molecular biology, forensic science, and genetic engineering are expected to fuel growing research and development activities in these areas, which will propel market expansion.

Healthcare providers' transition from real-time to digital technologies to drive the market. The development of Polymerase Chain Reaction devices has been significantly aided by the transition from real-time to digital diagnosis methods for a variety of disorders. Although real-time technology has been used extensively for clinical testing, its utility has been limited by a lack of standardization and comparatively low precision. Conversely, there are a number of advantages that digital technology offers over real-time PCR. It includes high precision, direct quantification, great sensitivity, and better reproducibility.

Comprehensive Analysis of Polymerase Chain Reaction (PCR) Market

The polymerase chain reaction (PCR) market and healthcare industry is rising with an exponential growth rate due to its market segmentation. Because of its market segmentation, the polymerase chain reaction (PCR) market and the healthcare sector are expanding at an exponential rate. This market expansion effectively provides a detailed regional assessment considering the dominant supply and demand forces that impact the pharmacy benefit management industry. These segmentations are methodically segregated by types, by product, by indication and by end users. The standard, real-time, and digital PCR segments are among the types; the instruments, reagents, and consumables are segmented by product; the infectious diseases, oncology, genetic disorders, and others are segmented by indication. Nonetheless, Diagnostic Centers, Hospitals & Clinics, Pharmaceutical & Biotechnology Industries, and Academic & Research Organizations are included in the end user segmentation.

The market for polymerase chain reaction (PCR) is expected to reach USD 3.66 billion in 2023, with North America leading the way due to consumers awareness of the availability of cutting-edge tools for accurate diagnosis and increasing prevalence of chronic illnesses that require accurate diagnosis and increasing need for sophisticated assays.

The leading companies in the market are essential to the healthcare industry because they guarantee industrial prospective growth and establish industry norms. These market players include BD (New Jersey, U.S.), QIAGEN (Hilden, Germany), Eppendorf AG (Hamburg, Germany), F. Hoffmann-La Roche Ltd (Basel, Switzerland), Bio-Rad Laboratories, Inc. (California, U.S.), Agilent Technologies, Inc. (California, U.S.), Abbott (Illinois, U.S.), Sysmex Inostics (Hyogo, Japan), and Thermo Fisher Scientific Inc. (Massachusetts, U.S.) are some of the players in this market.

In July 2021, The COVID-19 RT-Polymerase Chain Reaction test will also be available in India at PathStore at the pocket friendly cost as compared to other stores. The goal of this test is to maximize COVID-19 diagnosis in order to guarantee prompt therapy.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2032

Base Year 2023

Estimated Year 2024

Forecast Period 2024-2032

Historical Period 2019-2022

Growth Rate CAGR of 8.6% from 2024-2032

Unit Value (USD billion)

Segmentation By Type

Standard PCR
Real-time PCR
Digital PCR

By Product

Instruments
Reagents & Consumables

By Indication

Infectious Diseases
Oncology
Genetic Disorders
Others

By End User

Hospitals & Clinics
Pharmaceutical & Biotechnology Industries
Diagnostic Centers
Academic & Research Organizations

By Geography

North America (By Type, By Product, By Indication, By End User, and By Country)
U.S. (By Type)
Canada (By Type)
Europe (By Type, By Product, By Indication, By End User, and By Country)
U.K. (By Type)
Germany (By Type)
France (By Type)
Italy (By Type)
Spain (By Type)
Rest of Europe (By Type)
Asia Pacific (By Type, By Product, By Indication, By End User, and By Country)
China (By Type)
Japan (By Type)
India (By Type)
Australia (By Type)
Southeast Asia (By Type)
Rest of Asia Pacific (By Type)
Latin America (By Type, By Product, By Indication, By End User, and By Country)
Brazil (By Type)
Mexico (By Type)
Rest of Latin America (By Type)
Middle East & Africa (By Type, By Product, By Indication, By End User, and By Country)
GCC (By Type)
South Africa (By Type)
Rest of Middle East & Africa (By Type)

Please Note: It will take 5-6 business days to complete the report upon order confirmation.

1. Introduction: 1.1. Research Scope; 1.2. Market Segmentation; 1.3. Research Methodology; 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics: 3.1. Market Drivers; 3.2. Market Restraints; 3.3. Market Opportunities; 3.4. Market Trends
4. Key Insights: 4.1. Prevalence of Key Chronic Disorders, Key Countries, 2023; 4.2. Regulatory Scenario, By Key Countries/Regions; 4.3. Technological Advancements in Medical Aesthetic Devices; 4.4. New Product Launches, By Key Players; 4.5. Key Industry Developments- Mergers, Partnerships, & Acquisitions; 4.6. Impact of COVID-19 on the Market
5. Global Polymerase Chain Reaction (PCR) Market Analysis, Insights and Forecast, 2019-2032: 5.1. Market Analysis, Insights and Forecast – By Type; 5.1.1. Standard PCR; 5.1.2. Real-time PCR; 5.1.3. Digital PCR; 5.2. Market Analysis, Insights and Forecast – By Product; 5.2.1. Instruments; 5.2.2. Reagents & Consumables; 5.3. Market Analysis, Insights and Forecast – By Indication; 5.3.1. Infectious Diseases; 5.3.2. Oncology; 5.3.3. Genetic Disorders; 5.3.4. Others; 5.4. Market Analysis, Insights and Forecast – By End-user; 5.4.1. Hospitals & Clinics; 5.4.2. Pharmaceutical & Biotechnology Industries; 5.4.3. Diagnostic Centers; 5.4.4. Academic & Research Organization; 5.5. Market Analysis, Insights and Forecast – By Region; 5.5.1. North America; 5.5.2. Europe; 5.5.3. Asia Pacific; 5.5.4. Latin America; 5.5.5. Middle East & Africa
6. North America Polymerase Chain Reaction (PCR) Market Analysis, Insights and Forecast, 2019-2032: 6.1. Market Analysis, Insights and Forecast – By Type; 6.1.1. Standard PCR; 6.1.2. Real-time PCR; 6.1.3. Digital PCR; 6.2. Market Analysis, Insights and Forecast – By Product; 6.2.1. Instruments; 6.2.2. Reagents & Consumables; 6.3. Market Analysis, Insights and Forecast – By Indication; 6.3.1. Infectious Diseases; 6.3.2. Oncology; 6.3.3. Genetic Disorders; 6.3.4. Others; 6.4. Market Analysis, Insights and Forecast – By End-user; 6.4.1. Hospitals & Clinics; 6.4.2. Pharmaceutical & Biotechnology Industries; 6.4.3. Diagnostic Centers; 6.4.4. Academic & Research Organization; 6.5. Market Analysis, Insights and Forecast – By Country; 6.5.1. U.S.; 6.5.1.1. By Type; 6.5.2. Canada; 6.5.2.1. By Type
7. Europe Polymerase Chain Reaction (PCR) Market Analysis, Insights and Forecast, 2019-2032: 7.1. Market Analysis, Insights and Forecast – By Type; 7.1.1. Standard PCR; 7.1.2. Real-time PCR; 7.1.3. Digital PCR; 7.2. Market Analysis, Insights and Forecast – By Product; 7.2.1. Instruments; 7.2.2. Reagents & Consumables; 7.3. Market Analysis, Insights and Forecast – By Indication; 7.3.1. Infectious Diseases; 7.3.2. Oncology; 7.3.3. Genetic Disorders; 7.3.4. Others; 7.4. Market Analysis, Insights and Forecast – By End-user; 7.4.1. Hospitals & Clinics; 7.4.2. Pharmaceutical & Biotechnology Industries; 7.4.3. Diagnostic Centers; 7.4.4. Academic & Research Organization; 7.5. Market Analysis, Insights and Forecast – By Country/ Sub-region; 7.5.1. Germany; 7.5.1.1. By Type; 7.5.2. U.K.; 7.5.2.1. By Type; 7.5.3. France; 7.5.3.1. By Type; 7.5.4. Italy; 7.5.4.1. By Type; 7.5.5. Spain; 7.5.5.1. By Type; 7.5.6. Scandinavia; 7.5.6.1. By Type; 7.5.7. Rest of Europe; 7.5.7.1. By Type
8. Asia Pacific Polymerase Chain Reaction (PCR) Market Analysis, Insights and Forecast, 2019-2032: 8.1. Market Analysis, Insights and Forecast – By Type; 8.1.1. Standard PCR; 8.1.2. Real-time PCR; 8.1.3. Digital PCR; 8.2. Market Analysis, Insights and Forecast – By Product; 8.2.1. Instruments; 8.2.2. Reagents & Consumables; 8.3. Market Analysis, Insights and Forecast – By Indication; 8.3.1. Infectious Diseases; 8.3.2. Oncology; 8.3.3. Genetic Disorders; 8.3.4. Others; 8.4. Market Analysis, Insights and Forecast – By End-user; 8.4.1. Hospitals & Clinics; 8.4.2. Pharmaceutical & Biotechnology Industries; 8.4.3. Diagnostic Centers; 8.4.4. Academic & Research Organization; 8.5. Market Analysis, Insights and Forecast – By Country/ Sub-region; 8.5.1. India; 8.5.1.1. By Type; 8.5.2. China; 8.5.2.1. By Type; 8.5.3. Japan; 8.5.3.1. By Type; 8.5.4. Australia; 8.5.4.1. By Type; 8.5.5. Southeast Asia; 8.5.5.1. By Type; 8.5.6. Rest of Asia Pacific; 8.5.6.1. By Type
9. Latin America Polymerase Chain Reaction (PCR) Market Analysis, Insights and Forecast, 2019-2032: 9.1. Market Analysis, Insights and Forecast – By Type; 9.1.1. Standard PCR; 9.1.2. Real-time PCR; 9.1.3. Digital PCR; 9.2. Market Analysis, Insights and Forecast – By Product; 9.2.1. Instruments; 9.2.2. Reagents & Consumables; 9.3. Market Analysis, Insights and Forecast – By Indication; 9.3.1. Infectious Diseases; 9.3.2. Oncology; 9.3.3. Genetic Disorders; 9.3.4. Others; 9.4. Market Analysis, Insights and Forecast – By End-user; 9.4.1. Hospitals & Clinics; 9.4.2. Pharmaceutical & Biotechnology Industries; 9.4.3. Diagnostic Centers; 9.4.4. Academic & Research Organization; 9.5. Market Analysis, Insights and Forecast – By Country/ Sub-region; 9.5.1. Brazil; 9.5.1.1. By Type; 9.5.2. Mexico; 9.5.2.1. By Type; 9.5.3. Rest of Latin America; 9.5.3.1. By Type
10. Middle East & Africa Polymerase Chain Reaction (PCR) Market Analysis, Insights and Forecast, 2019-2032: 10.1. Market Analysis, Insights and Forecast – By Type; 10.1.1. Standard PCR; 10.1.2. Real-time PCR; 10.1.3. Digital PCR; 10.2. Market Analysis, Insights and Forecast – By Product; 10.2.1. Instruments; 10.2.2. Reagents & Consumables; 10.3. Market Analysis, Insights and Forecast – By Indication; 10.3.1. Infectious Diseases; 10.3.2. Oncology; 10.3.3. Genetic Disorders; 10.3.4. Others; 10.4. Market Analysis, Insights and Forecast – By End-user; 10.4.1. Hospitals & Clinics; 10.4.2. Pharmaceutical & Biotechnology Industries; 10.4.3. Diagnostic Centers; 10.4.4. Academic & Research Organization; 10.5. Market Analysis, Insights and Forecast – By Country/ Sub-region; 10.5.1. GCC; 10.5.1.1. By Type; 10.5.2. South Africa; 10.5.2.1. By Type; 10.5.3. Rest of Middle East & Africa; 10.5.3.1. By Type
11. Competitive Analysis: 11.1. Global Market Share Analysis (2023); 11.2. Company Profiles; 11.2.1. Bio-Rad Laboratories, Inc.; 11.2.1.1. Overview; 11.2.1.2. Products & Services; 11.2.1.3. SWOT Analysis; 11.2.1.4. Recent Developments; 11.2.1.5. Strategies; 11.2.1.6. Financials (Based on Availability); 11.2.2. QIAGEN; 11.2.2.1. Overview; 11.2.2.2. Products & Services; 11.2.2.3. SWOT Analysis; 11.2.2.4. Recent Developments; 11.2.2.5. Strategies; 11.2.2.6. Financials (Based on Availability); 11.2.3. F. Hoffmann-La Roche Ltd; 11.2.3.1. Overview; 11.2.3.2. Products & Services; 11.2.3.3. SWOT Analysis; 11.2.3.4. Recent Developments; 11.2.3.5. Strategies; 11.2.3.6. Financials (Based on Availability); 11.2.4. Agilent Technologies, Inc.; 11.2.4.1. Overview; 11.2.4.2. Products & Services; 11.2.4.3. SWOT Analysis; 11.2.4.4. Recent Developments; 11.2.4.5. Strategies; 11.2.4.6. Financials (Based on Availability); 11.2.5. Abbott; 11.2.5.1. Overview; 11.2.5.2. Products & Services; 11.2.5.3. SWOT Analysis; 11.2.5.4. Recent Developments; 11.2.5.5. Strategies; 11.2.5.6. Financials (Based on Availability); 11.2.6. Eppendorf AG; 11.2.6.1. Overview; 11.2.6.2. Products & Services; 11.2.6.3. SWOT Analysis; 11.2.6.4. Recent Developments; 11.2.6.5. Strategies; 11.2.6.6. Financials (Based on Availability); 11.2.7. Thermo Fisher Scientific Inc.; 11.2.7.1. Overview; 11.2.7.2. Products & Services; 11.2.7.3. SWOT Analysis; 11.2.7.4. Recent Developments; 11.2.7.5. Strategies; 11.2.7.6. Financials (Based on Availability); 11.2.8. Sysmex Inostic; 11.2.8.1. Overview; 11.2.8.2. Products & Services; 11.2.8.3. SWOT Analysis; 11.2.8.4. Recent Developments; 11.2.8.5. Strategies; 11.2.8.6. Financials (Based on Availability); 11.2.9. BD; 11.2.9.1. Overview; 11.2.9.2. Products & Services; 11.2.9.3. SWOT Analysis; 11.2.9.4. Recent Developments; 11.2.9.5. Strategies; 11.2.9.6. Financials (Based on Availability); 12.